Drug & intervention
talazoparib
RxCUI 2099704
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownA Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideNCT06844383 · 2026-05-04
RECRUITINGPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerNCT05873192 · 2025-06-03
RECRUITINGEvaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialNCT03990896 · 2021-11-18
RECRUITINGTalazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerNCT04734730 · 2021-05-04
RECRUITINGSelinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)NCT05035745 · 2021-03-01
RECRUITINGFUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) TestNCT06193525 · 2019-09-16
RECRUITINGPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerNCT05425862 · 2022-10-21
SUSPENDEDEfficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) SignatureNCT05288127 · 2022-03-08
UNKNOWNTreatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2mNCT05141708 · 2021-12-17
COMPLETEDA Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerNCT04690855 · 2021-10-04
TERMINATEDA Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsNCT04991480 · 2021-09-13
COMPLETEDCirculating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerNCT04849364 · 2021-08-24
TERMINATEDReal-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast CancerNCT04987931 · 2021-08-20
COMPLETEDTelaglenastat + Talazoparib In Prostate CancerNCT04824937 · 2021-07-01
UNKNOWNPhase Ia/Ib Talazoparib + Tazemetostat for mCRPCNCT04846478 · 2021-06-28
ACTIVE_NOT_RECRUITINGMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26
ACTIVE_NOT_RECRUITINGTalazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerNCT04703920 · 2021-03-04
COMPLETEDTalazoparib Maintenance Therapy in Triple-negative Breast CancerNCT04755868 · 2021-03-01
UNKNOWNThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWNEnzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)NCT04332744 · 2020-09-02
COMPLETEDEfficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaNCT04462809 · 2020-09-01
UNKNOWNTesting Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20
ACTIVE_NOT_RECRUITINGStudy of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerNCT04134884 · 2020-04-01
COMPLETEDCombination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)NCT04173507 · 2020-02-14
COMPLETEDAvelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsNCT04052204 · 2019-12-30
TERMINATEDStudy to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.NCT04039230 · 2019-10-09
ACTIVE_NOT_RECRUITINGA Study of the Drugs Talazoparib and Temozolomide in Prostate CancerNCT04019327 · 2019-07-11
TERMINATEDA Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerNCT03901469 · 2019-06-26
TERMINATEDStudy of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsNCT03875313 · 2019-05-20
TERMINATEDTALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerNCT03964532 · 2019-04-19
ACTIVE_NOT_RECRUITINGGedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersNCT03911973 · 2019-04-17
ACTIVE_NOT_RECRUITINGTalazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerNCT03672773 · 2018-10-31
ACTIVE_NOT_RECRUITINGTalazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerNCT03499353 · 2018-08-27
TERMINATEDA Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid TumorsNCT03343054 · 2017-11-30
COMPLETEDA Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerNCT03148795 · 2017-07-04
COMPLETEDLung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03
COMPLETEDTalazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT02567396 · 2016-06-01
WITHDRAWNTalazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerNCT02627430 · 2016-03-01
WITHDRAWNTalazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsNCT02537561 · 2015-12-01
WITHDRAWNTalazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast CancerNCT02282345 · 2015-04-16
COMPLETEDConditions being studied
Breast Cancer8Breast Neoplasms5Triple Negative Breast Cancer5Prostate Cancer4HER2/Neu Negative3Metastatic Breast Cancer3Metastatic Castration-resistant Prostate Cancer3TNBC - Triple-Negative Breast Cancer3ATM Gene Mutation2BRCA 1 Gene Mutation2BRCA 2 Gene Mutation2BRCA1 Gene Mutation2BRCA2 Gene Mutation2Estrogen Receptor Negative2Metastatic Castration Resistant Prostate Cancer (mCRPC)2Metastatic Ovarian Carcinoma2Metastatic Prostate Cancer2PALB2 Gene Mutation2Progesterone Receptor Negative2Prostate Cancer Metastatic2
Research locations
HoustonTexas, United States14New YorkNew York, United States14AtlantaGeorgia, United States9BostonMassachusetts, United States9IndianapolisIndiana, United States9MadisonWisconsin, United States9ChicagoIllinois, United States8Los AngelesCalifornia, United States8Ann ArborMichigan, United States7NashvilleTennessee, United States7AuroraColorado, United States6BarcelonaSpain6
Leading sponsors
Pfizer10National Cancer Institute (NCI)4M.D. Anderson Cancer Center3Massachusetts General Hospital3SWOG Cancer Research Network3Artios Pharma Ltd1Bryan Schneider, MD1Calithera Biosciences, Inc1City of Hope Medical Center1Dana-Farber Cancer Institute1Erasmus Medical Center1Fondazione per la Medicina Personalizzata1Georgetown University1Hospices Civils de Lyon1Jonsson Comprehensive Cancer Center1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.